|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-5.00/-3.29
|
Enterprise Value
2.96B
|
Balance Sheet |
Book Value Per Share
1.49
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
3.55M
|
Operating Revenue Per Share
2.06
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/12/24 12:52 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |